An Evaluation of Omega-3 Fatty Acid

Exclusion Criteria

• •1. Currently using fish oil capsules (supplements or prescription products).
• •2. Regular use of omega-3 supplements (defined as greater than 500 mg/week) within 4 weeks of study product administration.
• •3. Currently using any medications that may impact dietary fat absorption (i.e., Orlistat, Alli, etc.).
• •4. Currently using any medications that may interfere with omega-3 uptake (i.e. blood thinning medication or anticoagulants).
• •5. Currently using any lipid lowering medications (i.e. any cholesterol or triglyceride lowering agent).
• •6. Currently consuming high amounts of EPA \& DHA in the diet (as defined by greater than 200 mg/day by FFQ)
• •7. Currently following a self-reported no-fat or ultra-restrictive (less than 15%) Low-Fat Diet
• •8. Having the following medical conditions:
• •i. Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc.
• •ii. Hypertriglyceridemia (as defined by the Inclusion and per PI discretion; Total cholesterol \> 240 mg/dl; LDL \> 160 mg/dl; TG \> 199 mg/dl) iii. Type2 Diabetes Mellitus
• •9. Currently a smoker or nicotine user or has been nicotine free for less than 6 months
• •10. Use of any systemic medications, including OTC medications, herbal products, dietary supplements or vitamins (not previously listed) within 1 week of study product administration (occasional use of OTC analgesics such as acetaminophen may be allowed as judged by the Investigator)
• •11. Evidence or history of allergic or adverse responses to either study product, any of the product excipients or any comparable or similar products
• •12. Subjects who are not willing and not able to comply with scheduled visits and the requirements of the study protocol.
• •13. Female subjects who are breastfeeding, pregnant or plan to become pregnant during this study.
• •14. Current employee or immediate family member of the study sponsor or study site personnel.
• •15. Currently participating or have participated in another clinical trial within 4 weeks of study product administration
• •16. Donated blood, blood components, or significant loss of blood within 30 days of study product administration
• •17. History of a clinically-significant illness within 4 weeks of study product administration
• •18. History of hospitalization or treatment for clinically-significant drug or alcohol use/abuse within 1 year of dosing.
• •19. Subject has poor venous access or difficulty swallowing capsules
• •20. Any other issue which, in the judgment of the Investigator, will make the subject ineligible for study participation